| Drug General Information |
| Drug ID |
D0Y7IC
|
| Former ID |
DNCL002943
|
| Drug Name |
Baricitinib
|
| Drug Type |
Small molecular drug
|
| Indication |
Rheumatold arthritis; Psoriasis; Diabetic nephropathy [ICD9: 250, 250.4, 580-599, 696, 710-719, 714; ICD10:E08-E13, E10.2, E11.2, E13.2, L40, M00-M25, M05-M06, N00-N29]
|
Phase 3 |
[1],
[2]
|
|---|
| Company |
Eli Lilly; Incyte
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C16H17N7O2S
|
| InChI |
InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)
|
| InChIKey |
XUZMWHLSFXCVMG-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
85205106, 89960290, 103932354, 135313591, 136946415, 137856279, 144115683, 152258684, 160647521, 160703522, 162009736, 162011992, 162108950, 163312339, 164045123, 164194014, 170501894, 172087008, 172918187, 174006690, 174526483, 176250838, 185979207, 189561494, 198946894, 203105586, 208265518, 215785530, 223366123, 223375538, 223630418, 223705259, 224310310, 227140190, 244162815, 249733389, 249814474, 249816401, 252110203, 252160600, 252214958, 252443897, 252451786, 252553656
|
| Target and Pathway |
| Target(s) |
Tyrosine-protein kinase JAK2 |
Target Info |
Modulator |
[3]
|
|---|
| JAK1 |
Target Info |
Modulator |
[3]
|
|
KEGG Pathway
|
Chemokine signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Jak-STAT signaling pathway
|
|
Cholinergic synapse
|
|
Prolactin signaling pathway
|
|
Adipocytokine signaling pathway
|
|
Leishmaniasis
|
|
Toxoplasmosis
|
|
Tuberculosis
|
|
Measles
|
|
Influenza A
|
|
Herpes simplex infectionhsa04151:PI3K-Akt signaling pathway
|
|
Osteoclast differentiation
|
|
Hepatitis C
|
|
Hepatitis B
|
|
HTLV-I infection
|
|
Herpes simplex infection
|
|
Epstein-Barr virus infection
|
|
Pathways in cancer
|
|
Viral carcinogenesis
|
|
Pancreatic cancer
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
Interferon-gamma signaling pathway
|
|
JAK/STAT signaling pathway
|
|
PDGF signaling pathway
|
|
PI3 kinase pathway
|
|
CCKR signaling map STP00005:Angiogenesis
|
|
Pathway Interaction Database
|
Endothelins
|
|
ErbB4 signaling events
|
|
GMCSF-mediated signaling events
|
|
IL4-mediated signaling events
|
|
IL27-mediated signaling events
|
|
Signaling events mediated by PTP1B
|
|
IL12-mediated signaling events
|
|
S1P3 pathway
|
|
SHP2 signaling
|
|
CXCR4-mediated signaling events
|
|
IL5-mediated signaling events
|
|
IFN-gamma pathway
|
|
ErbB2/ErbB3 signaling events
|
|
IL3-mediated signaling events
|
|
IL6-mediated signaling events
|
|
PDGFR-beta signaling pathway
|
|
IL23-mediated signaling events
|
|
Signaling events mediated by Stem cell factor receptor (c-Kit)
|
|
EPO signaling pathway
|
|
Notch-mediated HES/HEY networkp73pathway:p73 transcription factor network
|
|
Signaling events mediated by TCPTP
|
|
IL2-mediated signaling events
|
|
IL2 signaling events mediated by PI3K
|
|
PDGFR-alpha signaling pathway
|
|
IL2 signaling events mediated by STAT5
|
|
Reactome
|
Interleukin-6 signaling
|
|
MAPK3 (ERK1) activation
|
|
MAPK1 (ERK2) activation
|
|
GPVI-mediated activation cascade
|
|
Prolactin receptor signaling
|
|
RMTs methylate histone arginines
|
|
G beta:gamma signalling through PI3Kgamma
|
|
Interleukin-3, 5 and GM-CSF signaling
|
|
RAF activation
|
|
RAF/MAP kinase cascade
|
|
Interferon gamma signaling
|
|
Regulation of IFNG signaling
|
|
Interleukin receptor SHC signaling
|
|
Growth hormone receptor signaling
|
|
Factors involved in megakaryocyte development and platelet productionR-HSA-1059683:Interleukin-6 signaling
|
|
ISG15 antiviral mechanism
|
|
Interleukin-7 signaling
|
|
Interleukin-2 signaling
|
|
Interferon alpha/beta signaling
|
|
Regulation of IFNA signaling
|
|
WikiPathways
|
Serotonin Receptor 2 and STAT3 Signaling
|
|
Type II interferon signaling (IFNG)
|
|
Notch Signaling Pathway
|
|
EPO Receptor Signaling
|
|
EGF/EGFR Signaling Pathway
|
|
IL-4 Signaling Pathway
|
|
IL-6 signaling pathway
|
|
Kit receptor signaling pathway
|
|
IL-3 Signaling Pathway
|
|
Mesodermal Commitment Pathway
|
|
Interleukin-2 signaling
|
|
Signaling by SCF-KIT
|
|
Prolactin receptor signaling
|
|
Growth hormone receptor signaling
|
|
JAK/STAT
|
|
BDNF signaling pathway
|
|
Oncostatin M Signaling Pathway
|
|
Interleukin-11 Signaling Pathway
|
|
AGE/RAGE pathway
|
|
TSLP Signaling Pathway
|
|
IL17 signaling pathway
|
|
Leptin signaling pathway
|
|
TSH signaling pathway
|
|
Interleukin-3, 5 and GM-CSF signaling
|
|
Interferon gamma signaling
|
|
Factors involved in megakaryocyte development and platelet production
|
|
IL-5 Signaling PathwayWP619:Type II interferon signaling (IFNG)
|
|
Interferon type I signaling pathways
|
|
TGF Beta Signaling Pathway
|
|
IL-2 Signaling Pathway
|
|
TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer
|
|
Interleukin-7 signaling
|
|
PDGF Pathway
|
|
Prostate Cancer
|
|
IL-9 Signaling Pathway
|
|
Type III interferon signaling
|
|
IL-7 Signaling Pathway
|
|
Integrated Breast Cancer Pathway
|
|
Integrated Cancer pathway
|
|
Interferon alpha/beta signaling
|
|
IL-5 Signaling Pathway
|
| References |
| REF 1 | ClinicalTrials.gov (NCT02265705) A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA). U.S. National Institutes of Health. |
|---|
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7792). |
|---|
| REF 3 | Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. |
|---|
